Apratastat
Modify Date: 2024-01-10 22:24:18
Apratastat structure
|
Common Name | Apratastat | ||
|---|---|---|---|---|
| CAS Number | 287405-51-0 | Molecular Weight | 414.496 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C17H22N2O6S2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of ApratastatApratastat is an orally active, potent, and reversible dual inhibitor of tumor necrosis factor-α converting enzyme (TACE) and matrix metalloproteinases (MMPs) . Apratastat can potently inhibit the release of TNF-α in vitro, ex vivo, and in vivo with IC50s of 144 ng/mL in vitro and 81.7 ng/mL ex vivo, respectively[1]. |
| Name | Apratastat |
|---|---|
| Synonym | More Synonyms |
| Description | Apratastat is an orally active, potent, and reversible dual inhibitor of tumor necrosis factor-α converting enzyme (TACE) and matrix metalloproteinases (MMPs) . Apratastat can potently inhibit the release of TNF-α in vitro, ex vivo, and in vivo with IC50s of 144 ng/mL in vitro and 81.7 ng/mL ex vivo, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
TNF-α MMP |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H22N2O6S2 |
| Molecular Weight | 414.496 |
| Exact Mass | 414.091919 |
| LogP | 1.42 |
| Index of Refraction | 1.607 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
|
ADAM17 mediates Nox4 expression and NADPH oxidase activity in the kidney cortex of OVE26 mice. Ford BM et al
Am. J. Physiol. Renal Physiol. 305(3) , F323-32, (2013)
|
|
|
Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach. Shu C et al
J. Clin. Pharmacol. 51(4) , 472-81, (2011)
|
| (3S)-N-Hydroxy-4-({4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholinecarboxamide |
| TMI 005 |
| (3S)-N-hydroxy-4-({4-[(4-hydroxybut-2-yn-1-yl)oxy]phenyl}sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide |
| MFCD13152357 |
| 3-Thiomorpholinecarboxamide, N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-, (3S)- |
| Apratastat |